Tekla Capital Management Decreased Its Celgene (CELG) Position by $10.02 Million; Senzar Asset Management Has Boosted Its Alder Biopharmaceuticals (ALDR) Stake by $1.00 Million

January 14, 2018 - By Clifton Ray

Senzar Asset Management Llc increased its stake in Alder Biopharmaceuticals Inc (ALDR) by 14.95% based on its latest 2017Q3 regulatory filing with the SEC. Senzar Asset Management Llc bought 83,400 shares as the company’s stock declined 24.25% while stock markets rallied. The hedge fund held 641,170 shares of the health care company at the end of 2017Q3, valued at $7.85M, up from 557,770 at the end of the previous reported quarter. Senzar Asset Management Llc who had been investing in Alder Biopharmaceuticals Inc for a number of months, seems to be bullish on the $1.21B market cap company. The stock decreased 0.28% or $0.05 during the last trading session, reaching $17.85. About 1.44 million shares traded or 31.59% up from the average. Alder Biopharmaceuticals, Inc. (NASDAQ:ALDR) has declined 33.67% since January 14, 2017 and is downtrending. It has underperformed by 50.37% the S&P500.

Tekla Capital Management Llc decreased its stake in Celgene Corporation (CELG) by 4.74% based on its latest 2017Q3 regulatory filing with the SEC. Tekla Capital Management Llc sold 69,080 shares as the company’s stock declined 3.49% while stock markets rallied. The institutional investor held 1.39 million shares of the major pharmaceuticals company at the end of 2017Q3, valued at $202.33M, down from 1.46 million at the end of the previous reported quarter. Tekla Capital Management Llc who had been investing in Celgene Corporation for a number of months, seems to be less bullish one the $83.46 billion market cap company. The stock increased 1.36% or $1.42 during the last trading session, reaching $106. About 8.75M shares traded or 5.20% up from the average. Celgene Corporation (NASDAQ:CELG) has risen 17.00% since January 14, 2017 and is uptrending. It has outperformed by 0.30% the S&P500.

Senzar Asset Management Llc, which manages about $442.00M and $409.74M US Long portfolio, decreased its stake in Anthem Inc (NYSE:ANTM) by 17,650 shares to 126,700 shares, valued at $24.06 million in 2017Q3, according to the filing. It also reduced its holding in Aerie Pharmaceuticals Inc (NASDAQ:AERI) by 160,200 shares in the quarter, leaving it with 231,200 shares, and cut its stake in Corium Intl Inc (NASDAQ:CORI).

Among 16 analysts covering Alder Biopharmaceuticals (NASDAQ:ALDR), 14 have Buy rating, 1 Sell and 1 Hold. Therefore 88% are positive. Alder Biopharmaceuticals had 31 analyst reports since August 6, 2015 according to SRatingsIntel. The firm has “Buy” rating by Aegis Capital given on Thursday, June 29. Piper Jaffray initiated Alder Biopharmaceuticals, Inc. (NASDAQ:ALDR) rating on Monday, October 31. Piper Jaffray has “Overweight” rating and $47 target. The rating was maintained by BMO Capital Markets with “Buy” on Tuesday, January 2. The stock of Alder Biopharmaceuticals, Inc. (NASDAQ:ALDR) has “Buy” rating given on Monday, January 8 by RBC Capital Markets. Needham maintained it with “Buy” rating and $3600 target in Thursday, June 8 report. As per Tuesday, June 27, the company rating was maintained by Piper Jaffray. RBC Capital Markets maintained the stock with “Buy” rating in Monday, October 16 report. Needham maintained the stock with “Buy” rating in Tuesday, June 27 report. The firm earned “Buy” rating on Monday, July 17 by Needham. The stock of Alder Biopharmaceuticals, Inc. (NASDAQ:ALDR) has “Buy” rating given on Wednesday, September 9 by Jefferies.

Tekla Capital Management Llc, which manages about $1.06 billion and $2.80 billion US Long portfolio, upped its stake in Accelerate Diagnostics Inc. (NASDAQ:AXDX) by 50,000 shares to 150,000 shares, valued at $3.37 million in 2017Q3, according to the filing. It also increased its holding in Acadia Healthcare Company Inc. (NASDAQ:ACHC) by 41,200 shares in the quarter, for a total of 272,400 shares, and has risen its stake in Abbott Laboratories (NYSE:ABT).

Since August 2, 2017, it had 0 insider purchases, and 5 selling transactions for $6.27 million activity. MARIO ERNEST sold $2.42 million worth of stock or 18,506 shares. Curran Terrie had sold 1,727 shares worth $248,498. 9,250 Celgene Corporation (NASDAQ:CELG) shares with value of $1.29 million were sold by CASEY MICHAEL D.

Analysts await Celgene Corporation (NASDAQ:CELG) to report earnings on January, 25. They expect $1.75 EPS, up 24.11% or $0.34 from last year’s $1.41 per share. CELG’s profit will be $1.38 billion for 15.14 P/E if the $1.75 EPS becomes a reality. After $1.78 actual EPS reported by Celgene Corporation for the previous quarter, Wall Street now forecasts -1.69% negative EPS growth.

Investors sentiment decreased to 1.17 in Q3 2017. Its down 0.17, from 1.34 in 2017Q2. It worsened, as 44 investors sold CELG shares while 457 reduced holdings. 133 funds opened positions while 451 raised stakes. 603.99 million shares or 0.25% more from 602.51 million shares in 2017Q2 were reported. Godshalk Welsh Capital Management holds 2,610 shares or 0.38% of its portfolio. Quantitative Invest Management Lc has 0.54% invested in Celgene Corporation (NASDAQ:CELG). Boyd Watterson Asset Mngmt Limited Liability Corp Oh owns 3,393 shares for 0.24% of their portfolio. Nikko Asset Americas holds 0.12% or 16,800 shares. Comerica owns 26,139 shares for 0.53% of their portfolio. 945 are held by Burt Wealth. Japan-based Sumitomo Mitsui Asset Communication Limited has invested 0.24% in Celgene Corporation (NASDAQ:CELG). Blackrock Inc, New York-based fund reported 55.47 million shares. Brandywine Glob Invest Mngmt Limited Liability has invested 0.35% in Celgene Corporation (NASDAQ:CELG). Cornercap Counsel Inc reported 0.17% of its portfolio in Celgene Corporation (NASDAQ:CELG). National Bank holds 0.2% in Celgene Corporation (NASDAQ:CELG) or 3,386 shares. 734,940 are held by Great West Life Assurance Can. Advisory Research Incorporated accumulated 1,642 shares. Massachusetts-based Peddock Capital Advsrs Llc has invested 1.07% in Celgene Corporation (NASDAQ:CELG). Clark Management Gru stated it has 126,078 shares or 0.62% of all its holdings.

Among 33 analysts covering Celgene Corporation (NASDAQ:CELG), 18 have Buy rating, 2 Sell and 13 Hold. Therefore 55% are positive. Celgene Corporation had 124 analyst reports since July 21, 2015 according to SRatingsIntel. Piper Jaffray maintained it with “Hold” rating and $100.0 target in Thursday, December 21 report. The stock of Celgene Corporation (NASDAQ:CELG) has “Buy” rating given on Thursday, January 7 by SunTrust. The rating was maintained by Citigroup with “Neutral” on Friday, October 27. The firm has “Buy” rating given on Thursday, December 21 by Guggenheim. The stock of Celgene Corporation (NASDAQ:CELG) earned “Hold” rating by Standpoint Research on Wednesday, November 9. The rating was maintained by BMO Capital Markets with “Outperform” on Friday, October 27. The firm earned “Buy” rating on Friday, October 20 by Stifel Nicolaus. Canaccord Genuity maintained it with “Buy” rating and $156.0 target in Monday, October 16 report. The stock of Celgene Corporation (NASDAQ:CELG) has “Outperform” rating given on Tuesday, April 19 by Credit Suisse. On Friday, October 27 the stock rating was maintained by SunTrust with “Buy”.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

By

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our FREE daily email newsletter:


Recent Market News

>